Loading stock data…
CEL-SCI Corporation (CVM)
$1.08-0.03 (-2.70%)
After Hours$1.07-0.01 (-0.93%)· Last close Jun 29
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CEL-SCI Corporation in the Healthcare sector is trading at $1.08 with a market capitalization of $15M. The stock is currently near its 52-week low of $0.89, remaining 78.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.33M↑ | -$5.37M↑ | -$6.03M↓ | -$5.49M↑ | -$6.39M |
| Net Income | -$5.47M | -$5.47M↑ | -$6.10M↓ | -$5.66M↑ | -$6.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has complete...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-330.21%
Volume
Today's trading volume
331,567
Recent News
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month
Cel-Sci priced the share offering at $1, a 7.4% discount from the stock’s previous close.
Cel-Sci: Fiscal Q1 Earnings Snapshot
VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Tuesday reported a loss of $5.5 million in its fiscal first quarter.
Cel-Sci: Fiscal Q3 Earnings Snapshot
VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Thursday reported a loss of $5.7 million in its fiscal third quarter.